Meanwhile, Biogen also reported data from a long-term extension phase from the two studies, which showed a continued effect on biomarkers for the disease up to two and a half years. The antibody ...

This article was written by the Bloomberg Enterprise Investment Research Data team: Sundeep Agrawal, Maris Serzans, and Jerome Barkate. Amid an increasingly volatile macroeconomic climate shaped ...

Top-line data from the Phase 3 part of RISE UP, a clinical trial testing mitapivat in people with sickle cell disease (SCD), are expected by the end of the year, according to developer Agios ...

PeakForce Tapping in magnetic force microscopy offers superior spatial resolution and sensitivity, enabling precise mapping ...

Research informs the resources we create so you can support kids' healthy development in the digital age. Below you'll find reliable, independent data about the impact of media and tech on kids’ ...

a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient's immune system against the breadth of the patient's own ...

LUND, SE / ACCESS Newswire / May 14, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...

Beyond funding, one in five affected researchers reported that key data sources are no longer accessible. Seventeen said software or datasets essential to their work had vanished or were no longer ...

The abstracts published online today summarize the clinical results from the company’s completed Phase 2 trial of mavorixafor in the treatment of certain primary chronic neutropenic (CN) disorders.

providing access to data from 75 million insured individuals (90% of the country’s population)—offer unprecedented opportunities to advance digital health innovation and research with global ...